CO5170515A1 - Agentes inmunopotenciadores tenciadores y composiciones farmaceuticas que los contienen - Google Patents

Agentes inmunopotenciadores tenciadores y composiciones farmaceuticas que los contienen

Info

Publication number
CO5170515A1
CO5170515A1 CO00035829A CO00035829A CO5170515A1 CO 5170515 A1 CO5170515 A1 CO 5170515A1 CO 00035829 A CO00035829 A CO 00035829A CO 00035829 A CO00035829 A CO 00035829A CO 5170515 A1 CO5170515 A1 CO 5170515A1
Authority
CO
Colombia
Prior art keywords
alkyl
phenyl
ch2c
thienyl
tenciadores
Prior art date
Application number
CO00035829A
Other languages
English (en)
Inventor
Lawrence Camillo Creemer
Herring Janice Rhea
Edward Deorsey Mcgruder
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of CO5170515A1 publication Critical patent/CO5170515A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • C07D451/06—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/30—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom
    • C07D211/32—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by doubly bound oxygen or sulfur atoms or by two oxygen or sulfur atoms singly bound to the same carbon atom by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/78—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Una composición inmunopotenciadora la cual comprende un vehículo portador fisiológicamente aceptable y una cantidad inmunopotenciadora eficaz de un compuesto definido por la siguiente Fórmula I:<EMI FILE="00035829_1" ID="1" IMF=JPEG >en donde:R1 es H, alquil C1-C4 ó (=O);R2 es C(O)R8, CH2C(O)R8, CN, CH2OH, OH, OC(O)R9 ú OS(O)2R9;R3, R4 y R5 son cada uno independientemente H ó alquil C1-C4;R6 es C(O)OCH2Ar3, C(O)NHCH2Ar3, C(O)Ar1, C(O)CH(R3)Ar2, C(O)CH(R3)CH2Ar2, C(O)CH(R3)CH2CH2Ar4 ó C(O)NHR9;R7 es H ó CH2C(O)R8;R8 es H, alquil C1-C4, OR10, NHR11 ú OH (cuando R6 es C(O)Ar1 ó C(O)CH(R3)Ar2);R9 es alquil C1-C4;R10 es alquil C2-C8, CH2CH2N(CH3)2 ó CH3(cuando R6 es C(O)Ar1 y Ar1 es fenil);R11 es alquil C2-C6, CH2CH2N(CH3)2 ó alquil C7-C9 (cuando R6 es C(O)Ar1);Ar1 es fenil, 4-fluorofenil, 2Ar3 es fenil; -tienil, 3-tienil ó 1,4-bifenil;Ar2 es fenil ó 2-tienil;Ar4 es 2-tienil;halo es CI, Br ó F; yAr6 es fenil ó 4-fluorofenil;con la condición de que cuando R7 sea CH2C(O)R8, entonces R2 y R3 son H, R4 y R5 son H ó alquil C1-C4; R6 es C(O)CH(R3)Ar4; R8 es H, alquil C1-C4, OR9 ó NHR10; R9 es alquil C1-C8 y R10 es alquil C2-C8; y con la condición adicional de que cuando R1 sea (=O), entonces R2 es C(O)R8 ó CH2C(O)R8; R3, R4 y R5 son H ó alquil C1-C4; R6 es C(O)OCH2Ar3, C(O)Ar6 ó C(O)NHR9; R7 es H ó, junto con R5, CH2CH2: R8 es H, alquil C1-C4, OR10 ó NHR11; R9 es alquil C1-C4; R10 es alquil C1-C8 y R11 es alquil C2-C8; ...
CO00035829A 1999-05-21 2000-05-17 Agentes inmunopotenciadores tenciadores y composiciones farmaceuticas que los contienen CO5170515A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13533899P 1999-05-21 1999-05-21

Publications (1)

Publication Number Publication Date
CO5170515A1 true CO5170515A1 (es) 2002-06-27

Family

ID=22467653

Family Applications (1)

Application Number Title Priority Date Filing Date
CO00035829A CO5170515A1 (es) 1999-05-21 2000-05-17 Agentes inmunopotenciadores tenciadores y composiciones farmaceuticas que los contienen

Country Status (5)

Country Link
US (1) US6664271B1 (es)
AU (1) AU4971600A (es)
CO (1) CO5170515A1 (es)
PE (1) PE20010131A1 (es)
WO (1) WO2000071519A2 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1341762A1 (en) * 2000-11-20 2003-09-10 Eli Lilly And Company Process for resolving racemic mixtures of piperidine derivatives
MX2012010038A (es) 2010-03-16 2012-10-01 Aventis Pharma Inc Una pirimidina sustituida como un antagonista del receptor de la prostaglandina d2.

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485014A1 (fr) * 1980-06-20 1981-12-24 Pharmindustrie Nouveaux derives de (quinolyl-2, -3 ou -4)-1 (piperidyl ou pyrrolidinyl-2 ou -3)-2 ou -3 ethanone ou propanone, procedes pour leur preparation, et leur utilisation comme medicaments
FR2508445A1 (fr) * 1981-06-29 1982-12-31 Sori Soc Rech Ind Nouveaux derives de benzoyl-phenyl-piperidine, leur procede de preparation et leur application, notamment en therapeutique
CA2111463C (en) * 1991-06-19 1997-08-26 Bingwei V. Yang Azaspiro quinolone antibacterial agents
US5242783A (en) * 1991-07-31 1993-09-07 Eastman Kodak Company Photographic material and process
CA2122397A1 (en) * 1993-05-03 1994-11-04 Spencer D. Kimball Guanidinyl- or amidinyl-substituted heterocyclic thrombin inhibitors
US5741800A (en) * 1993-06-22 1998-04-21 Knoll Aktiengesellachaft Azolyl-cyclic amine derivates with immunomodulatory activity
US5561146A (en) * 1994-06-10 1996-10-01 Bristol-Myers Squibb Company Modified guanidino and amidino thrombin inhibitors
WO1998046569A1 (fr) 1997-04-11 1998-10-22 Sumitomo Pharmaceuticals Co., Ltd. Derives de benzene
EP1341762A1 (en) * 2000-11-20 2003-09-10 Eli Lilly And Company Process for resolving racemic mixtures of piperidine derivatives

Also Published As

Publication number Publication date
PE20010131A1 (es) 2001-02-09
US6664271B1 (en) 2003-12-16
WO2000071519A3 (en) 2001-04-26
WO2000071519A2 (en) 2000-11-30
AU4971600A (en) 2000-12-12

Similar Documents

Publication Publication Date Title
CO5261559A1 (es) Antagonistas de neurokinina selectivos
CO5150159A1 (es) Derivados de 4-arilquinolin-2-ona 3-substituida como moduladores de los canales de potasio
TW568896B (en) Calcium receptor-active compounds
CO5140119A1 (es) 3-substituido-n-(hetero)arilalquil-pirrolidinas
CO5140093A1 (es) Epotilonas c 21 modificadas
CO5390047A1 (es) Derivados de uk-2a
CO5261539A1 (es) Compuestos farmaceuticamente activos
CO5150176A1 (es) Antagonistas iii del receptor ccr-3 de los receptores ccr-3 composicio farmaceutica que los con- tiene y procedimiento para la preparacion de estos compues- tos.
CO5170512A1 (es) Derivados de tetrahidroquinolin piperidina
CO4970730A1 (es) Tetrahidro prostaglandinas aromaticas c16-c20 sustituidas utilies como agonistas fp
AR031597A1 (es) Compuestos piperidinos,un proceso para su preparacion, composiciones farmaceuticas,y el uso de dichos compuestos para la fabricacion de un medicamento para uso como inhibidores ccr-3
CO5271737A1 (es) Tioamidas de oxazolidinona con substituyentes de piperazin-amida
CO5390082A1 (es) Compuestos organicos
CO5420196A1 (es) Compuestos inhibidores de metaloproteasa bidentes, composi- ciones farmaceuticas que los contienne y metodos para su utilizacion
AR003138A1 (es) Composicion farmaceutica para tratar canceres y virus con (1h-1,2,4- triazoles) y composicion de unidad de dosis que la comprende
AR015964A1 (es) Compuestos de isoquinolina, su uso, procedimiento para tratar una afeccion, procedimiento de preparacion del compuesto, composicion farmaceutica que locontiene y compuesto util en dicho procedimiento
CO5280081A1 (es) Antibacterianos de piperidiniloxi oxazolidinona, composicion farmaceutica que los comprende y proceso para su preparacion
CO5170515A1 (es) Agentes inmunopotenciadores tenciadores y composiciones farmaceuticas que los contienen
CO5221041A1 (es) Compuestos de 3-(fenil sustituido)-5-tienil-1.2.4- triazolo con actividad contra la mosca blanca y composiciones insecticidas que lo contienen
CO5261596A1 (es) Derivados de cromano como compuestos estrogenicos, y su uso en la fabricacion de medicamentos para tratamientos relaionados con los receptores de estrogenos
AR013360A1 (es) Derivados de 6-azauracilo inhibidores de il-5, procedimiento para su preparacion, composicion que los contiene, procedimiento para preparardicha composicion, uso de dicho compuesto para la manufactura de medicamentos, de composiciones y procedimiento de marcado de un receptor.
CO5231155A1 (es) Benzoilciclohexanodionas substituidas
CO5080785A1 (es) Derivados heterociclicos
CO5200762A1 (es) Preparacion de piperidin-4-onas sustituidas
CO5210898A1 (es) Combinaciones sienrgicas de fungicida del tipo valinamida y fenamidona